GUIDE-HF was the only CardioMEMS randomized controlled trial that enrolled patients based on NT-proBNP values within 30 days before study consent, yet treatment effect heterogeneity based on NT-proBNP strata were not reported [11]. This evidence concerns the gene NPPB and hydrops fetalis.